Keyword: H. Lundbeck

Kyowa Hakko Kirin has posted a look at proof-of-concept data on adenosine A2A receptor antagonist KW-6356 in early Parkinson’s disease patients.

The buyout gives Lundbeck control of an mGluR4 positive allosteric modulator designed to improve the long-term symptom control of dopaminergic agents.

Lundbeck chief Schultz will lead Teva, former CDC director Frieden leads a new health project, Roivant named Eisai exec Waxman as general counsel.

Merck has halted a phase 2/3 Alzheimer’s disease trial after an interim analysis found it was destined to fail.

Lundbeck is calling time on development of Alzheimer’s candidate idalopirdine after it chalked up a clean sweep of failures in phase 3.

Lundbeck has struck a deal with Ossianix to use shark-derived antibodies to hustle drugs across the blood-brain barrier.

Lundbeck and Takeda's Brintellix has failed to beat the placebo in a Phase II trial in adult ADHD patients

Lundbeck has chalked up another Phase III failure for the Alzheimer's field. Neither dose hit the primary endpoint or showed separation from placebo.

Danish drug developer Lundbeck has upgraded to the latest version of ArisGlobal's regulatory and safety platform. The decision, which follows a review of the alternatives, will see Lundbeck move to a fully outsourced hosted system, a model it thinks will lower its upgrade and maintenance costs while freeing it to focus on its core business.